Despite a 17% stock decline over the past year, Vertex is considered one of the most profitable large-cap stocks by analysts. Goldman Sachs reiterated its Buy rating with a $624 price target following the company's announcement of strong fiscal second-quarter results. This analyst confidence underscores a bullish outlook on the pharmaceutical firm's performance and future potential.